ImmuCell Corporation EBITDA for the Trailing 12 Months (TTM) ending March 31, 2023: USD -2.42 M

ImmuCell Corporation EBITDA is USD -2.42 M for the Trailing 12 Months (TTM) ending March 31, 2023, a -162.12% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.
  • ImmuCell Corporation EBITDA for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 3.89 M.
  • ImmuCell Corporation EBITDA for the Trailing 12 Months (TTM) ending March 31, 2019 was USD 814.10 K.
Key Data
Date EBITDA Net Income EPS (Diluted) Shares (Diluted, Weighted)